| KAYSER, Sabine, Michael KRAMER, David MARTINEZ-CUADRON, Justin GRENET, Klaus H METZELER, Zuzana ŠUSTKOVÁ, Marlise R LUSKIN, Andrew M BRUNNER, Michelle A ELLIOTT, Cristina GIL, Sandra Casal MARINI, Zdeněk RÁČIL, Petr CETKOVSKY, Jan NOVAK, Alexander E PERL, Uwe PLATZBECKER, Friedrich STOELZEL, Anthony D HO, Christian THIEDE, Richard M STONE, Christoph ROELLIG, Pau MONTESINOS, Richard F SCHLENK and Mark J LEVIS. Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study. Haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2022, vol. 107, No 4, p. 836-843. ISSN 0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2021.278645. |
Other formats:
BibTeX
LaTeX
RIS
@article{2251509,
author = {Kayser, Sabine and Kramer, Michael and MartinezandCuadron, David and Grenet, Justin and Metzeler, Klaus H and Šustková, Zuzana and Luskin, Marlise R and Brunner, Andrew M and Elliott, Michelle A and Gil, Cristina and Marini, Sandra Casal and Ráčil, Zdeněk and Cetkovsky, Petr and Novak, Jan and Perl, Alexander E and Platzbecker, Uwe and Stoelzel, Friedrich and Ho, Anthony D and Thiede, Christian and Stone, Richard M and Roellig, Christoph and Montesinos, Pau and Schlenk, Richard F and Levis, Mark J},
article_location = {PAVIA},
article_number = {4},
doi = {http://dx.doi.org/10.3324/haematol.2021.278645},
keywords = {acute myeloid leukemia; FLT3-ITD},
language = {eng},
issn = {0390-6078},
journal = {Haematologica},
title = {Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study},
url = {https://haematologica.org/article/view/haematol.2021.278645},
volume = {107},
year = {2022}
}
TY - JOUR
ID - 2251509
AU - Kayser, Sabine - Kramer, Michael - Martinez-Cuadron, David - Grenet, Justin - Metzeler, Klaus H - Šustková, Zuzana - Luskin, Marlise R - Brunner, Andrew M - Elliott, Michelle A - Gil, Cristina - Marini, Sandra Casal - Ráčil, Zdeněk - Cetkovsky, Petr - Novak, Jan - Perl, Alexander E - Platzbecker, Uwe - Stoelzel, Friedrich - Ho, Anthony D - Thiede, Christian - Stone, Richard M - Roellig, Christoph - Montesinos, Pau - Schlenk, Richard F - Levis, Mark J
PY - 2022
TI - Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study
JF - Haematologica
VL - 107
IS - 4
SP - 836-843
EP - 836-843
PB - FERRATA STORTI FOUNDATION
SN - 03906078
KW - acute myeloid leukemia
KW - FLT3-ITD
UR - https://haematologica.org/article/view/haematol.2021.278645
N2 - The aim of this study was to evaluate the prognostic impact of FLT3-ITD in core-binding factor acute myeloid leukemia (CBF-AML) in an international, multicenter survey of 97 patients of whom 52% had t( 8; 21)(q22;q22) and 48% had inv(16)(p13q22)/t(16;16)(p13;q22). The median age of the patients was 53 years (range, 19-81). Complete remission after anthracycline-based induction (n= 86) and non-intensive therapy (n=11) was achieved in 97% and 36% of the patients, respectively. The median follow-up was 4.43 years (95% confidence interval [95% CI]: 3.35-7.39 years). The median survival after intensive and non-intensive treatment was not reached and 0.96 years, respectively. Among intensively treated patients, inv(16) with trisomy 22 (n=11) was associated with a favorable 4-year relapse-free survival rate of 80% (95% CI: 59-100%) as compared to 38% (95% CI: 27-54%; P=0.02) in all other patients with CBF-AML/FLT3-ITD (n= 75). Overall, 24 patients underwent allogeneic hematopoietic cell transplantation (HCT), 12 in first complete remission and 12 after relapse. Allogeneic HCT in first complete remission was not beneficial (P=0.60); however, allogeneic HCT seemed to improve median survival in relapsed patients compared to that of patients treated with chemotherapy (not reached vs. 0.6 years, respectively; P=0.002). Excluding patients with inv(16) with trisomy 22, our data indicate that the outcome of CBF-AML patients with FLT3-ITD may be inferior to that of patients without FLT3-ITD (based on previously published data), suggesting that prognostically CBF-AML patients with FLT3-ITD should not be classified favorable-risk. FLT3-inhibitors may improve the outcome of these patients.
ER -
KAYSER, Sabine, Michael KRAMER, David MARTINEZ-CUADRON, Justin GRENET, Klaus H METZELER, Zuzana ŠUSTKOVÁ, Marlise R LUSKIN, Andrew M BRUNNER, Michelle A ELLIOTT, Cristina GIL, Sandra Casal MARINI, Zdeněk RÁČIL, Petr CETKOVSKY, Jan NOVAK, Alexander E PERL, Uwe PLATZBECKER, Friedrich STOELZEL, Anthony D HO, Christian THIEDE, Richard M STONE, Christoph ROELLIG, Pau MONTESINOS, Richard F SCHLENK and Mark J LEVIS. Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study. \textit{Haematologica}. PAVIA: FERRATA STORTI FOUNDATION, 2022, vol.~107, No~4, p.~836-843. ISSN~0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2021.278645.
|
